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TAR DNA-binding protein 43 (TDP-43) is a key player in neurodegenerative diseases including 
frontotemporal lobar degeneration (FTLD) and amyotrophic lateral sclerosis (ALS). Accumulation of 
TDP-43 is associated with neuronal death in the brain. How increased and disease-causing mutant 
forms of TDP-43 induce cell death remains unclear. Here we addressed the role of TDP-43 during 
neural development and show that reduced TDP-43 causes defects in neural stem/progenitor cell 
proliferation but not cell death. However, overexpression of wild type and TDP-43A315T proteins induce 
p53-dependent apoptosis of neural stem/progenitors and human induced pluripotent cell (iPS)-derived 
immature cortical neurons. We show that TDP-43 induces expression of the proapoptotic BH3-only 
genes Bbc3 and Bax, and that p53 inhibition rescues TDP-43 induced cell death of embryonic mouse, 
and human cortical neurons, including those derived from TDP-43G298S ALS patient iPS cells. Hence, 
an increase in wild type and mutant TDP-43 induces p53-dependent cell death in neural progenitors 
developing neurons and this can be rescued. These findings may have important implications for 
accumulated or mutant TDP-43 induced neurodegenerative diseases.
The nucleotide binding protein TDP-43 regulates a multitude of cellular processes including gene transcription, 
RNA splicing, mRNA stability, localization and translation, and microRNA biogenesis1. TDP-43 is associated 
with most cases of FTLD and ALS. Point mutations and elevated TDP-43 levels cause FTLD-TDP coupled with 
neuronal death. Affected neurons have nuclear depletion and cytoplasmic accumulation of TDP-43. Interestingly, 
accumulation of TDP-43 in neurons is characteristic of many neurodegenerative diseases in addition to 
FTLD-TDP and ALS, including Alzheimer’s disease. TDP-43 seems to play roles in the onset and progression 
of neurodegeneration but mechanistically how it triggers and contributes to disease and cell death is not known.
TDP-43 was originally identified as a factor binding to the TAR DNA of human immunodeficiency virus 
where it is implicated in transcriptional regulation2. It belongs to the family of heterogeneous nuclear ribonu-
cleoproteins (hnRNP) and is ubiquitously expressed. Deletion of the Tardbp (the gene encoding TDP-43) in mice 
leads to early embryonic lethality between E3.5 and E6.53,4 indicating an important role during early develop-
ment. TDP-43 contains two RNA-recognition motifs (RRMs), RRM-1 and RRM-2, and a glycine-rich region at its 
C-terminus5. The RRM-1 is necessary and sufficient for nucleic acid binding to single stranded RNA at GU-rich 
sequences6. The C-terminus of TDP-43 is necessary for the formation of hnRNP-rich complexes7 and contains 
most of the TDP-43 point mutations identified in FTLD and ALS patients. TDP-43 is localized predominantly 
nuclear in cells and has both a nuclear localization sequence (NLS) and a predicted nuclear export sequence 
(NES) and seems to be continuously shuttled between the two cellular compartments8.
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TDP-43 is one of the main components of cytoplasmic inclusions, which are a characteristic feature of many 
neurodegenerative disorders. Apoptotic neurons that display cytoplasmic inclusions show a partial loss of TDP-
43 in the nucleus9, which was suggested to drive, at least in part, disease pathogenesis. However, the cause and 
function of TDP-43 aggregates remains to be shown unequivocally. In mice, robust cytoplasmic TDP-43 aggrega-
tion is associated with dramatic neuron loss and features of human pathology, which can be reversed by increased 
clearance of TDP-4310. Interestingly, mislocalization of TDP-43 to the cytoplasm of mouse neurons is sufficient to 
induce apoptosis even in the absence of aggregation, suggesting that cytoplasmic TDP-43 aggregates may not be 
necessary to induce cell death and early mortality in mice9,11–13.
Aberrant TDP-43 causes pleiotropic effects in cells and results in extensive changes in splicing and RNA 
metabolism14. Cross-linked immunoprecipitation and RNA sequencing (CLIP-Seq) revealed that TDP-43 can 
bind thousands of RNAs via a UG-rich consensus sequence in the 3′ untranslated regions of target RNAs15–17. 
Whereas the RNAs bound by TDP43 in the mouse brain are relatively consistent in the different analyses, TDP-43 
targets vary considerably between cell types16,17.
Aggregates in diseased neurons contain hyper-phosphorylated and fragmented TDP-43 protein. Interestingly, 
TDP-43 can be cleaved by caspases18, and other factors of the apoptosis pathway including Bim, Bax and Bcl may 
be involved in TDP-43-induced cell death19. Components of the proapoptotic pathway are downstream targets 
of p53 and elevated p53 levels have been detected in affected neurons of ALS patients20,21. However, the absence 
of p53 in a transgenic mouse model for ALS (hSOD1G93A) did not rescue apoptosis, suggesting that cell death in 
these animals occurred in a p53-independent manner22,23. Although aberrant TDP-43 expression is associated 
with stress responses24, a causal link between p53 and TDP-43 induced cell death has not been reported. TDP-43 
is expressed in the developing and adult brain, therefore, we addressed the role of TDP-43 during development 
of the telencephalon by gain- and loss-of-function experiments. We thereby hoped to gain insights into TDP-43 
functions in the formation and maintenance of the nervous system.
Here we show that expression of TDP-43 and its mutant form TDP-43A315T results in p53-mediated apoptosis 
in neural stem/progenitor cells and immature neurons of the developing mouse telencephalon. In addition, we 
observed cell death of cortical neurons derived from human iPS cells following TDP-43 expression and found that 
this neuronal death could also be rescued by p53-inhibition. Expression of the proapoptotic BH3-only genes Bbc3 
and Bax was increased in mice and human neural cells as a result of aberrant TDP-43 expression, supporting a 
role for p53 in the TDP-43 induced cell death. Furthermore, we show that TDP-43 is associated with the mRNA 
of Cdkn1a and increases Cdkn1a levels, likely explaining the altered neural stem/progenitor cell cycle regulation 
following TDP-43 and TDP-43A315T expression.
Results
TDP-43 controls cell cycle, neurogenesis and is toxic for neural progenitors. Tardbp is expressed 
by neural progenitors in the developing central nervous system (Supplementary Fig. 1a)3. In the developing tel-
encephalon at e14.5, TDP-43 protein is prominent in ventricular zone stem/progenitor cells including by those in 
M-phase of the cell cycle at the ventricular surface where expression partially overlaps with phospho-Histone H3 
(pH3) (Fig. 1a, arrowheads, Supplementary Fig. 1b). TDP-43 protein expression is also prominent in differentiat-
ing neurons in the cortical plate (Fig. 1b).
To address the functions of TDP-43 during forebrain development, we knocked-down (KD) TDP-43 in vivo 
targeting the ventricular zone stem and progenitor cells by in utero electroporation (IUE) with hairpin RNAs 
targeting its mRNA (shTDP-43). TDP-43 mRNA and protein levels were reduced in neural progenitors by up 
to ~70% 48 hours after transfection (Fig. 1c, Supplementary Fig. 2a–d). The percentage of transfected cells that 
expressed detectable levels of TDP-43 in vivo reduced from 93.9 +/− 4.2% in controls to 3.7 +/− 2.5% in shTDP-
43 transfected embryos (Supplementary Fig. 2c,d). TDP-43 KD increased the number of progenitors in M-phase 
within 24 hours (pH3+: Fig. 1d,e), as well as those entering S-phase (BrdU labeled) (Fig. 1f). These effects were 
consistent with the expression of TDP-43 by mitotic cells in the developing telencephalon. TDP-43 KD also 
reduced the number of Pax6+ ventricular zone progenitors and increased the generation of Tbr2+ basal progen-
itors slightly (p = 0.07) (Fig. 1d,g,h and Supplementary Fig. 2e–h). After 48 hours, the increase in BrdU+ cells 
in the ventricular zone following TDP-43 KD was still evident but the formation of Tbr2+ basal progenitors 
had returned to normal and there were no obvious effects on cell survival (Supplementary Fig. 2i,j and data not 
shown).
Conversely, the moderate (2.4-fold) increase in wild type TDP-43 expression induced by IUE (Fig. 2a,b) 
resulted in an increase in active caspase-3 expressing cells and rapid apoptotic death of most neural progenitors in 
vivo (Fig. 2c,d). TDP-43 expression reduced not only the absolute number but also the proportion of Pax6+ cells 
remaining in the developing telencephalon (Fig. 2e). The few surviving TDP-43 overexpressing cells that were 
undergoing mitosis were displaced from their normal position at the ventricular lining (Fig. 2f,g). Furthermore, 
the differentiation of neural stem/progenitor cells into basal progenitors (Tbr2+) was reduced and generation of 
newborn neurons (Tbr1+) in the cortical plate was blocked by TDP-43 overexpression indicating cell death and 
impaired neuronal differentiation (Fig. 2h,i and Supplementary Fig. 3). These data suggested that overexpression 
of wild type TDP-43 in neural progenitors of the developing telencephalon is toxic, induces changes in cell pro-
liferation and blocks neurogenesis.
Mutant TDP-43A315T induces p53-dependent cell death. Autosomal dominant mutations in human 
TDP-43 are sufficient to cause familial ALS and FTLD. Disease causing mutations occur predominantly in the 
C-terminal prion-domain of TDP-4325. The mechanisms of mutant TDP-43 induced toxicity remain unclear but 
are associated with an increase in TDP-43 protein levels26. We examined the effects of mutant TDP-43 expression 
in neural progenitors in vivo. Mutant human TDP-43A315T (Fig. 2a), like wild type TDP-43, induced cell death 
and caspase-3 activation when expressed by IUE in neural progenitors in vivo (Fig. 2c). TDP-43A315T expression 
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resulted in a loss of Pax6+ progenitors in the ventricular zone and aberrant differentiation into basal progenitors 
(Tbr2+) (Fig. 2e,h). These data indicate that mutant TDP-43A315T partially phenocopied the effects seen after 
overexpression of wild type TDP-43.
TDP-43 induced cell death is p53-dependent. p53-dependent neuronal cell death occurs in several 
neurodegenerative diseases27. Given that TDP-43 induces cell death, the link between TDP-43 cleavage and 
caspases, and demonstration of elevated p53 in neurons of ALS patients20,21, we investigated whether TDP-43 
Figure 1. TDP-43 knockdown (KD) decreases Pax6+ neural stem/progenitors and affects cell cycle. (a) 
TDP-43 is expressed by ventricular zone (VZ) progenitors including by cells in mitosis (arrows). (b) TDP-
43 is highly expressed by neurons in the cortical plate (CP) at e14.5. (c) TDP-43 KD (shTDP-43) by in utero 
electroporation (IUE) of neural stem/progenitors at e13.5 and analyzed at e14.5 reduces TDP-43 mRNA levels 
by 70% (***P < 0.001) compared to control (shRenilla). (d) TDP-43 KD (GFP+) cells survive in the VZ and 
differentiate to generate Tbr2+ basal progenitors in the subventricular zone (SVZ) similar to control transfected 
cells (shRenilla). (e) The proportion of cells lining the ventricle that are pH3+ increases following TDP-43 KD 
(shTDP-43) compared to control cells (shRenilla: Ctrl.), suggesting accumulation in M-phase of cell cycle. 
Values are shown as the proportion of transfected cells (GFP+). (f) Scheme of the BrdU labeling procedure in 
e13.5 mice with a BrdU pulse 22.5 hours post IUE and 1.5 hours prior to killing. The proportion of GFP+ cells in 
the VZ that are BrdU labeled following TDP-43 KD (shTDP-43) increases compared to control cells (shRenilla: 
Ctrl.), suggesting increased S-phase entry. Values are shown as the proportion of transfected cells (GFP+). (g) 
The proportion of GFP+ cells that are Pax6+ following TDP-43 KD (shTDP-43) reduces compared to control 
cells (shRenilla: Ctrl.). Values are shown as the proportion of transfected cells (GFP+). (h) The proportion of 
GFP+ cells that are Tbr2+ following TDP-43 KD (shTDP-43) is unaffected compared to control cells (shRenilla: 
Ctrl.). Values are shown as the proportion of transfected cells (GFP+). Scale bars in a and d = 25 µm, in 
b = 100 µm. Dashed line marks the telencephalic vesicle lining. tTest *P < 0.05, ***< 0.001. ventricular zone 
(VZ), subventricular zone (SVZ), cortical plate (CP).
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induced apoptosis of neural progenitors cells depends on p53 activity. In contrast to expression in control (p53wt) 
embryos, IUE-mediated TDP-43 overexpression in p53-deficient embryos (p53−/−) did not disrupt neural pro-
genitors in the ventricular zone or affect their morphology (Fig. 3a).
To separate potential cell autonomous and non-autonomous effects of TDP-43 overexpression, we performed 
a mosaic deletion of Trp53 combined with IUE of TDP-43. We analyzed mice carrying Hes5::CreERT2 and Rosa26 
floxed STOP transcription GFP Cre reporter (Rosa-CAG::GFP) alleles, to lineage trace the Cre-expressing neural 
stem/progenitor cells and their progeny, which were either wild type or homozygous for floxed Trp53 alleles. We 
induced deletion of Trp53 from ventricular zone progenitors in embryos at e11 by Tamoxifen induction28 and 
expressed TDP-43 by IUE in these embryos at e13.5 (Supplementary Fig. 4a,b). Under these mosaic conditions, 
TDP-43 overexpressing cells that were wild type for Trp53 (GFP-) underwent apoptosis (caspase-3) (Fig. 3b,c). 
Conversely, TDP-43 overexpressing cells where Trp53 had been deleted (GFP+) were viable and showed a normal 
morphology (Fig. 3b,c). By this conditional approach, loss of p53 also rescued the reduction in Pax6+ progenitors 
and the proliferation defects (pH3+ and BrdU labeling) induced by TDP-43 overexpression (Fig. 3d–f). This sug-
gested that the cell death caused by TDP-43 is a p53-dependent cell autonomous response and not the result of 
disruption of the neural progenitor zones in the developing telencephalon.
Similarly, injection of the pharmacological inhibitor of p53, Pifithrin-α (PFT-α)29,30, into p53wt mothers res-
cued TDP-43 overexpressing cells and blocked caspase-3 activation (Fig. 4a,b). We analyzed PFT-α rescued cells 
in greater detail and found that the number and integrity of ventricular zone progenitors (Pax6+) and basal 
progenitors (Tbr2+) were comparable to controls (Fig. 4b,c and data not shown). Mitotically active cells (pH3+) 
Figure 2. Expression of TDP-43 and TDP-43A315T induce p53-dependent apoptosis of neural progenitors. (a) 
Scheme of human TDP-43 and TDP-43A315T with a single point mutation in the glycine-rich C-terminal region, 
nuclear localization signal (NLS), nuclear export signal (NES), RNA recognition motif (RRM). (b) Transfection 
of neural progenitors results in a 2.4-fold expression of TDP-43 and 2.8-fold for TDP-43A315T compared to 
endogenous levels. Expression of Cdkn1 reduces endogenous TDP-43 levels suggesting a reciprocal interaction 
with TDP-43. (c) Expression of TDP-43 and TDP-43A315T activates caspase-3 (arrows) and drives cells in the 
ventricular zone into apoptosis within 24 hours. (d) TDP-43 and TDP-43A315T expression induce caspase-3 
activity and apoptosis in transfected cells (GFP+). Values are shown as the proportion of transfected cells 
(GFP+). (e) TDP-43 and TDP-43A315T expression reduce the proportion of Pax6+GFP+ progenitors compared 
to control transfected cells (Ctrl.). Values are shown as the proportion of transfected cells (GFP+). (f,g) TDP-43 
expression causes mislocalization of GFP+pH3+ cells away from the ventricular lining (GFP control: arrows) to 
more basal locations (TDP-43: arrowheads) and reduces the proportion of ventricular progenitors in M-phase 
(pH3+) compared to control transfected cells (Ctrl.). Values are shown as the proportion of transfected cells 
(GFP+). (h) TDP-43 and TDP-43A315T expression reduce differentiation to Tbr2+ basal progenitors compared 
to control transfected cells (Ctrl.). Values are shown as the proportion of transfected cells (GFP+). (i) TDP-43 
overexpressing progenitors fail to generate Tbr1+ neurons in the cortical plate. Scale bar in c and f = 25 µm. 
Dashed line marks the telencephalic vesicle lining. tTest *P < 0.05, **< 0.01, ***< 0.001.
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were decreased upon TDP-43 expression, but this was not rescued by inhibition of p53 (Fig. 4d). Furthermore, 
PFT-α treatment did not induce a change in the number of pH3+ cells lining the ventricle in control (35.6 +/− 3.1 
versus 39.0 +/− 1.8%) or TDP-43 overexpressing embryos (18.1 +/− 2.8% versus 23.4 +/− 3.0) (compare Figs 2g 
and 4d). Reduced proliferation in the ventricular zone following TDP-43 overexpression was also supported by 
BrdU incorporation experiments with less labeled cells in the TDP-43 overexpressing embryos even after PFT-α 
treatment (Fig. 4e). These findings are suggestive of two independent mechanisms of action for TDP-43 overex-
pression, one triggering p53-dependent apoptosis and a second perturbing cell cycle dynamics that likely does 
not involve p53.
RNA recognition motif 1 of TDP-43 is critical for toxicity. The underlying mechanisms through which 
TDP-43 induces cell death are unclear. Both full length as well as truncated and C-terminal fragments of TDP-
43 accumulate in aggregates during neurodegeneration31. TDP-43 binds thousands of RNAs, including its own, 
regulating many aspects of RNA biogenesis, stability, splicing and transport15,16,32. The RNA recognition motif 
1 (RRM1) of TDP-43 is necessary and sufficient for RNA binding6,33. We addressed whether RNA binding is 
required for TDP-43 induced toxicity in neural progenitors by expressing a mutant form where the RRM1 had 
been deleted (TDP-43∆RRM1) (Supplementary Fig. 5a,b). Unlike TDP-43 and TDP-43A315T, expression of TDP-
43∆RRM1 in neural progenitors did not result in obvious signs of cell death in vivo (Supplementary Fig. 5c). The 
number of ventricular zone progenitors (Pax6+) and basal progenitors (Tbr2+) were comparable to controls fol-
lowing TDP-43∆RRM1 expression (Supplementary Fig. 5d–f). This indicated that functional RNA binding of TDP-
43 is crucial in the cell death response and aberrant neurogenesis induced by TDP-43.
TDP-43 and TDP-43A315T induce p53 targets and proapoptotic gene expression. TDP-43 and 
TDP-43A315T induced cell death was blocked by PFT-α. TDP-43 and TDP-43A315T increased Trp53 mRNA and 
p53 protein levels consistent with an activation of a stress response (Fig. 5a,b). In addition to the increase in total 
p53 levels, the phosphorylated and active form of p53 was also increased substantially following TDP-43 and 
TDP-43A315T expression (Fig. 5b). p53 regulates proapoptotic gene expression including Bbc3 (PUMA) and Bax 
as well as cell cycle regulators including Cdkn1a. Consistent with an activation of p53, TDP-43 and TDP-43A315T 
induced Bbc3 and Bax expression in neural progenitors but not the antiapoptotic gene Bcl2 (Fig. 5c). In contrast, 
Figure 3. p53 deletion rescues TDP-43 overexpressing neural progenitors. (a) TDP-43 overexpression does 
not induce cell fragmentation or death of progenitors of p53−/− embryos. p53−/− TDP-43 expressing cells show 
a normal radial morphology in the ventricular zone and migrate to the subventricular zone. (b,c) Conditional 
deletion of floxed Trp53 alleles by expression of Cre-recombinase (GFP+), (mCherry+GFP+p53−/−, arrows) 
reduces caspase-3 activation following expression of TDP-43 compared to none Cre-recombined cells 
(mCherry+GFP-p53+/+, arrowheads). Values are shown as the proportion of TDP-43 overexpressing cells 
(mCherry+). (d–f) Trp53 ablated (GFP+), TDP-43 overexpressing (mCherry+) cells (mCherry+GFP+p53−/−, 
arrows) show rescue of Pax6+ (d), BrdU+ (e) and pH3+ expression (f) compared to none Cre-recombined Trp53 
wild type cells (mCherry+GFP−p53+/+). Values are shown as the proportion of transfected cells (mCherry+). 
Scale bar = 25 µm. Dashed line marks the telencephalic vesicle lining. tTest P = 0.06, **< 0.01, ***< 0.001.
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TDP-43∆RRM1 overexpression did not affect p53 or proapoptotic gene expression (Fig. 5a,c). The balance between 
pro- and antiapoptotic genes regulates entry into the apoptotic pathway by stimulating mitochondrial perme-
ability, the release of cytochrome C, and activation of caspase-9 and caspase-334. Bbc3 binds Bcl2 releasing the 
proapoptotic BH3-only proteins Bax and Bak. Hence, Bbc3 induced by TDP-43 via p53 could bind and inhibit 
Bcl2, and the concomitant enhanced Bax expression would result in increased cell death.
Cdkn1a is a direct transcriptional target of p53. TDP-43 and TDP-43A315T but not TDP-43∆RRM1 induced 
Cdkn1a expression (Fig. 5a). PFT-α treatment did not affect the expression of the endogenous Tardbp but signifi-
cantly inhibited TDP-43 and TDP-43A315T induced Trp53 and Cdkn1a expression (Fig. 5d). Hence, overexpression 
of TDP-43 and a mutant form, TDP-43A315T, result in activation of multiple p53 target genes and this requires the 
RRM1 domain.
Cdkn1a mRNA associates with TDP-43. As TDP-43 reduced cell cycle, and induced Cdkn1a expression 
(Figs 2–5), we examined the cell cycle defects in more detail. Therefore, we assessed a potential TDP-43 regu-
lation of Trp53 and Cdkn1a by CLIP (cross-linked RNA immunoprecipitation). In accordance with previous 
findings15,16,32,35, TDP-43 bound and decreased endogenous Tardbp mRNA levels (Fig. 5e and Supplementary 
Fig. 6a,b). In addition, Cdkn1a but not Trp53 mRNA was CLIPed together with TDP-43 (Fig. 5e and 
Supplementary Fig. 6a) and expression of TDP-43 and TDP-43A315T translated into an increase in Cdkn1a protein 
in N2A cells (Supplementary Fig. 6c). Hence, although PFT-α reduced Trp53 and Cdkn1a mRNA expression in 
neural progenitors in vitro (Fig. 5d), and rescued cell death, Cdkn1a protein levels still increased in response to 
TDP-43, likely as a result of regulation of Cdkn1a at the post-transcriptional level. We did not observe an inter-
action between TDP-43 and p53 or Cdkn1a at the protein level (Supplementary Fig. 6d). Forced expression of 
Cdkn1a by IUE resulted in exit of progenitor cells from the ventricular zone and their exit from the cell cycle but, 
unlike TDP-43 overexpression, did not induce cell death or precocious differentiation (Supplementary Fig. 7a–d). 
Interestingly, we observed a reciprocal down regulation of TDP-43 mRNA and protein expression following over-
expression of Cdkn1a (Supplementary Fig. 6b and Fig. 2b). Hence, TDP-43 regulates Cdkn1a expression that 
potentially contributes to the changes in cell cycle and explains the insensitivity of these effects to p53 inhibition.
p53 inhibition partially rescues TDP-43A315T embryos. Homozygous mice expressing TDP-43A315T 
from the Tardbp locus (Tardbp315/315) die in utero (Supplementary Fig. 7a)36. The cause of death is unclear but 
post-implantation e6.5 mutant embryos were developmentally retarded, showed hemorrhage around the prim-
itive endoderm and limited trophectodermal expansion and infiltration. At e9.5 most Tardbp315/315 embryos 
were dead and the few remaining mutants were severely developmentally delayed and died soon thereafter 
Figure 4. p53 inhibition with PFT-α rescues TDP-43 mediated apoptosis and integrity but not cell cycle 
defects. (a) TDP-43 induced caspase-3 activity and apoptosis is rescued by blocking p53 with PFT-α. (b) 
Inhibition of p53 with PFT-α in utero rescues TDP-43 induced apoptosis but does not reverse cell cycle defects. 
Arrows indicate BrdU+ transfected cells (GFP+). (c) Inhibition of p53 with PFT-α rescues TDP-43 expressing 
Pax6+ progenitors in embryos. (d) The proportion of TDP-43 overexpressing cells (GFP+) at the ventricular 
lining and expressing pH3+ is reduced and not rescued by PFT-α compared to control transfected cells (Ctrl.). 
Values are shown as the proportion of transfected cells (GFP+). (e) The proportion of TDP-43 overexpressing 
cells (GFP+) in the VZ that are BrdU labeled is not rescued by PFT-α compared to control cells (Ctrl.). 
Values are shown as the proportion of transfected cells (GFP+). Scale bars = 25 µm. Dashed line marks the 
telencephalic vesicle lining. tTest *P < 0.05, ***< 0.001.
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(Supplementary Fig. 8a). We treated pregnant Tardbpwt/315 females from Tardbpwt/315 inter-crosses with PFT-α 
every day after day 3.5 post-coitum. Inhibition of p53 in utero rescued Tardbp315/315 embryos past e7.5 to 
Mendelian ratios up to e14.5 (Supplementary Fig. 8b,c). The PFT-α rescued mice looked phenotypically normal 
although slightly smaller than age-matched siblings. Brain morphology and development did not show obvious 
defects and proliferation within the brain of e14.5 Tardbp315/315 embryos was indistinguishable from wild type 
siblings (Supplementary Fig. 8d,e). In order to address whether loss of p53 was able to rescue Tardbp315/315 mice 
to birth, we inter-crossed Tardbpwt/315 and Trp53−/− mice to generate Tardbp315/315, p53−/− animals. However, after 
analysis of >100 offspring, we were unable to find Tardbp315/315 mice in multiple litters from different parents. 
Hence, inhibition of p53 with PFT-α rescued early embryonic death of Tardbp315/315 mutant mice but inhibition 
of p53 function is unable to rescue Tardbp315/315 embryos to birth.
TDP-43 induced cell death of human iPS-derived cortical neurons can be rescued by blocking p53. 
TDP-43 and TDP-43A315T expression induces p53-dependent apoptosis in the developing mouse telencephalon. 
In order to assess the effects of accumulated TDP-43 on human cortical cells, we differentiated human iPS cells to 
cortical progenitors and neurons for 39 days (Fig. 6a)37. Expression of wild type TDP-43 and mutant TDP-43A315T 
at day 37 caused a loss of human iPS-derived cortical cells within 48 hours including neurons and progenitors 
(Fig. 6b–d). The surviving TDP-43 overexpressing cells had stunted morphologies and pyknotic nuclei (Fig. 6b). 
Figure 5. TDP-43 regulates proapototic BH3-only, Trp53 and Cdkn1a mRNA expression. (a) TDP-43 
and TDP-43A315T expression in neural progenitors increases Trp53 and Cdkn1a mRNA levels, analyzed by 
quantitative RT-PCR analysis. TDP-43∆RRM1expression does not affect Trp53 and Cdkn1a mRNA levels. (b) 
TDP-43 and TDP-43A315T expression in neural progenitors results in increased level of activated, phosphorylated 
p53 protein and total p53 protein. (c) TDP-43 and TDP-43A315T expression in neural progenitors increases 
mRNA levels of the proapoptotic BH3-only proteins Bbc3 (PUMA) and Bax, but not the antiapoptotic factor 
Bcl2. TDP-43∆RRM1expression does not affect Bbc3, Bax or Bcl-2 mRNA levels. (d) Pharmacological inhibition of 
p53 reduces TDP-43 and TDP-43A315T induced Trp53 and Cdkn1a mRNA levels but does not affect endogenous 
Tardbp mRNA expression, analyzed by quantitative RT-PCR analysis. Values are shown as relative to non-
treated, standardized to β-actin. (e) TDP-43 binds endogenous Tardbp and Cdkn1a but not Trp53 mRNAs. 
Quantitative RT-PCR analysis of Tardbp, Cdkn1a, Trp53 and β-actin transcripts CLIPed together with TDP-43 
from neural progenitors. Values are fold enrichment over control CLIPed (flag-GFP) transcripts. Statistical 
analysis of CLIPed products corrected relative to input RNA concentrations compared to flag-GFP CLIPed 
samples. Agarose gel analysis of the amplicons is shown in Supplementary Fig. 6a.
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Treatment of TDP-43 and TDP-43A315T expressing human iPS-derived cortical cultures with the PFT-α for the last 
44 hours of culture rescued cell number and partially rescued the loss of neurons and progenitors and reduced the 
number of active caspase-3 expressing cells (Fig. 6c–f). Hence, TDP-43 accumulation in human cortical neurons 
can also induce p53-dependent neuronal cell death.
TDP-43 induces increased proapoptotic gene expression in human iPS-derived cortical 
cells. As TDP-43 overexpression in human iPS-derived cortical cells induced cell death, we examined whether 
this involved increased expression of the proapototic genes BBC3, BAX and the antiapototic gene BCL2. We trans-
fected iPS-derived cortical cells at day 37 of differentiation, sorted the TDP-43 overexpressing human cortical 
cells (GFP+) after 48 hours and examined gene expression by qRT-PCR. In agreement with our findings in the 
mouse telencephalon, overexpression of TDP-43 in human cells significantly increased the expression of TRP53, 
CDKN1A, BBC3, and BAX but also BCL2 (Fig. 7a). We examined whether the increase in proapoptotic gene 
expression in response to TDP-43 overexpression was dependent upon p53 activity by treating the cells for the last 
44 hours of culture with PFT-α. Blocking p53 activity prevented the increase in TRP53, CDKN1A, BBC3, BAX and 
BCL2 expression above the levels seen in PFT-α treated control cultures, suggesting that also in human cortical 
Figure 6. TDP-43 and human mutant TDP-43A315T toxicity in human iPS-derived neurons is rescued by 
inhibition of p53. (a) Scheme of the human iPS cortical neuron differentiation profile and analysis of TDP-43 
overexpression. Control human iPS cells were neuralized from day 0 to day 12 in N2-B27 Medium + LDN 
and SB and passaged on day 15 and day 25 and differentiated in N2 medium minus B27 (N2-B27) for 39 days. 
TDP-43 and TDP-43A315T expression constructs were transfected on day 37. (b) Transfected GFP-expressing 
human iPS cells have neuronal and progenitor morphologies. TDP-43 and TDP-43A315T cells are reduced 
and show stunted morphologies and cellular fragmentation compared to controls (arrows). (c) Expression of 
TDP-43 and TDP-43A315T reduces the number of iPS-derived cells within the cultures. Treatment with PFT-α 
for 44 hours significantly rescues the number of transfected cells to control (GFP) levels. Together with the 
increased expression of activated caspase-3 these findings confirm that TDP-43 and TDP-43A315T are toxic and 
rapidly induce apoptotic cell death that is dependent upon p53. (d,e) TDP-43 and TDP-43A315T expression result 
in a reduction of iPS-derived neurons (βIII-Tubulin+) and progenitors cells (βIII-Tubulin−). PFT-α treatment 
of the cultures for 44 hours prior to analysis partially rescued the TDP-43 and TDP-43A315T induced loss of 
neurons and progenitors. (f) TDP-43 and TDP-43A315T expressing human neurons activate caspase-3 and die 
by apoptosis. Inhibition of p53 with PFT-α for 44 hours rescues cell death. Scale bar = 25 µm. tTest *P < 0.05, 
**< 0.01, ***< 0.001, ns not significant.
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cells, the expression of TDP-43 induces a p53-dependent increase in proapoptotic genes that may contribute to 
the observed cell death (Fig. 7b).
TDP-43 mutations are associated with neurodegenerative disease including FTLD and ALS. We used 
patient-derived TDP-43G298S mutant iPS cells38 and differentiated them into cortical neurons using the same pro-
tocol used for differentiation of the control human iPS cells (Fig. 6a). These cortical cultures contained activated 
caspase-3+ neurons and treatment with PFT-α for 44 hours reduced the number of apoptotic neurons suggesting 
p53 activity in these cultures (Fig. 7c). In agreement with p53-mediated neuronal cell death, PFT-α treatment 
significantly increased the number of neurons derived from TDP-43G298S patient iPS cells (Fig. 7d). Therefore, we 
examined the expression levels of TRP53, CDKN1A, BBC3, BAX and BCL2 in the TDP-43G298S mutant iPS-derived 
cortical cultures. Trp53 expression was significantly higher in the TDP-43G298S-derived cells compared to control. 
In support of an increased p53 activity, the expression of BBC3, BAX and BCL2 were all elevated in the TDP-
43G298S iPS cortical neuron cultures. In addition, treatment of the iPS-derived cultures with PFT-α to block p53, 
significantly reduced expression of BBC3, BAX and BCL2 in TDP-43G298S but not by control iPS-derived cortical 
neurons (Fig. 7e).
Discussion
Our findings identify activation of proapototic gene expression as a mechanism through which TDP-43 accumu-
lation and mutations can induce cell death in murine neural progenitors in vivo and human cortical neurons in 
vitro. This effect was rescued by blocking or depleting p53. p53 is induced by cellular stress and recent findings 
indicate that TDP-43 accumulation, as seen in neurodegenerative diseases including ALS and FTLD, induces cel-
lular stress response24,39–41. Thus, it is possible that induced p53 in our paradigms is also a result of cellular stress 
caused by the accumulation of TDP-43. In addition, TDP-43 induces phosphorylation of Eif2α, which results in 
a general inhibition of translation30. Eif2α phosphorylation induces translation of ATF4 (activating transcription 
factor 4), which enhances expression of ATF3 and CHOP (CCAAT/enhancer-binding protein homologous pro-
tein). CHOP inhibits Bcl2 functions at the protein level and induces Bim to enhance cell death through activation 
Figure 7. Proapoptotic gene expression is increased in human iPS-derived cortical cells and TDP-43G298S 
mutant iPS derived cortical cultures. (a) TDP-43/GFP expression in human iPS followed by fluorescent assisted 
cell sorting after 48 hours. TDP-43 expression in human iPS cortical neuron increases mRNA levels of the 
proapoptotic genes Trp53, Cdkn1a, Bbc3 (PUMA), Bax and Bcl2. (b) TDP-43/GFP expression in human iPS 
followed by sorting after 48 hours. p53 inhibition by PFT-α treatment for 44 hours prior to sorting rescues TDP-
43 induced increase of proapoptotic genes in human iPS compared to control. (c) TDP-43G298S iPS-derived cells 
show reduced numbers of activated caspase-3+ cells upon PFT-α treatment for 44 hours. (d) TDP-43G298S iPS 
cells and control iPS cells show reduced numbers of βIII-Tubulin+ cells upon PFT-α treatment for 44 hours. 
(e) TDP-43G298S iPS cells display increases mRNA levels of proapoptotic genes p53, Bbc3 (PUMA), Bax and 
Bcl2 upon PFT-α treatment for 44 hours. In comparison mRNA levels of the very genes in Control iPS cells are 
unchanged. tTest *P < 0.05, **< 0.01, ***<0.001 relative to control cells. #P < 0.05, ##P < 0.01 relative to cells not 
treated with PFT-α.
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of Bax. In agreement, we found that neither TDP-43 nor TDP-43A315T induce Bcl2 expression in mouse cells, 
whereas Bax is increased. However, it is conceivable that Eif2α inhibition of antiapoptotic BH3-only proteins and 
the p53-induced proapoptotic gene (Bbc3 and Bax) expression synergize to promote cell death in TDP-43 mutant 
cells. Hence, TDP-43 seems to activate a bifurcated pathway to control BH3-only protein-mediated apoptosis.
Increase of TDP-43 and TDP-43A315T in cortical neurons derived from human iPS cells also resulted in an 
apoptosis phenotype. In concordance with the overexpression in mouse cells, we observed a strong increase in 
TRP53, CDKN1A, BBC3 and BAX in the human cortical neural cells in vitro. However, BCL2 was also increased 
in the human cortical neurons in contrast to mouse neural progenitor cells. This opposing result might stem from 
differences in pathway regulation between species. However, inhibition of p53 by PFT-α rescued the TDP-43 
mediated increase in the proapoptotic genes in mouse neural progenitor cells and human cortical neurons.
Besides the TDP-43 mediated increase in p53, we also observed a strong increase in Cdkn1a mRNA levels. 
Concomitant, we observed that TDP-43 overexpression induced a block in cell cycle progression in mouse neu-
ral progenitors in vivo. Cdkn1a is activated by p53, however, we additionally show an association of TDP-43 to 
Cdkn1a mRNA, which suggests a regulation of Cdkn1a expression by TDP-43. This is supported by the obser-
vation that blocked cell cycle progression could not be rescued by p53 inhibition. Thus, TDP-43 expression not 
only induces apoptosis but also induces a cell cycle block, probably at G2/M phase transition through cyclin 
dependent kinase inhibition via Cdkn1a, which in turn could stimulate cell death. Due to the fact that we per-
formed the CLIP experiments with PFA cross-linking, we cannot be sure that TDP-43 binds directly to Cdkn1a 
mRNA. Confirmation of direct binding of TDP-43 to Cdk1a mRNA will require further analysis. Previously, it has 
been reported that TDP-43 overexpression induces G2/M arrest in HeLa cells42. It was shown that the effect was 
partially dependent on p53 but apoptosis could not be rescued by p53-inhibition. These partially contradictory 
results may be explained by the differences in cells used in the experiments. HeLa cells have an altered cell cycle 
regulation and might not respond in the fashion as neural progenitors and neurons to inhibition of p53.
Many lines of transgenic mice expressing wild type or mutant forms of TDP-43 have been analyzed in the 
last years, all of which show early mortality. We employed homozygous mice expressing TDP-43A315T and par-
tially rescued the animals by p53 inhibition. Similar rescue experiments have been preformed in hSOD1G82A 
transgenic mice. Interestingly, p53 deletion did not rescue the early lethality in these hSOD1G82A animals, which 
indicates a p53-independent mechanism, possibly involving death receptors34. This is supported by findings that 
death receptor 6 (DR6) levels are elevated in hSOD1G82A transgenic mice43. In addition, treatment with blocking 
antibodies against DR6 increased motor neuron survival and, therefore, provided a neuroprotective effect in 
hSOD1G82A expressing animals. The partial rescue of TDP-43A315T embryos indicates probable involvement of 
additional factors triggering lethality of these animals. However, this remains to be addressed in the future.
We also investigated how loss of TDP-43 affects cell survival and differentiation of neural stem/progenitor 
cells. In striking contrast to the overexpression experiments, we did not observe signs of apoptosis upon KD of 
TDP-43 in vivo. Although TDP-43 is indispensable for early development3, it does not seem to have a crucial 
function in neural progenitor maintenance in the brain at the time points we analyzed. This might be due to the 
fact that we only achieved a 70% reduction in TDP-43 levels at the protein level. However, we did observe a signif-
icant increase in the number of proliferating cells in the in vivo KD experiment. Cdkn1a KD induces proliferation 
by promoting S-phase entry44. We hypothesize that loss of TDP-43 results in a reduction in Cdkn1a, which in turn 
activates proliferation, reduces cell cycle exit and delays differentiation.
In conclusion, we show that TDP-43 accumulation in mouse neural progenitors in vivo as well as in human 
cortical progenitors and neurons and in TDP-43G298S mutant iPS-derived cortical cultures induces p53-dependent 
apoptosis. This is associated with up regulation of apoptotic genes including Bbc3 and Bax. We did not observe 
a direct interaction between TDP-43 and p53 on the protein or mRNA levels. It therefore remains elusive how 
TDP-43 activates p53 expression but this is likely, at least in part, to be indirect via induction of cellular stress 
response30. Future work should address this as well as how the multiple pathways downstream of TDP-43 con-
tribute to cell death in disease.
Methods
Animals and animal husbandry. Trp53tm1Tyj, Trp53tm1Brn, TDP-43A315T, Rosa-CAG::GFP and Hes5::CreERT2 
mice have been described elsewhere28,36,45–47. Mice were maintained on a 12-hour day/night cycle with adequate 
food and water under SPF conditions. All methods were carried out in accordance with guidelines and regula-
tions of Max-Planck Institutional and German Federal regulations and under license numbers H-05/01, 0-06/02, 
G-09/18, G-09/19, G-08/26 (Ethical Commission Freiburg, Germany) and 2437 and 2438 (Veterinary commis-
sion Basel). All experimental protocols were approved by Max-Planck Institutional and German Federal regula-
tions and under license numbers H-05/01, 0-06/02, G-09/18, G-09/19, G-08/26 (Ethical Commission Freiburg, 
Germany) and 2437 and 2438 (Veterinary commission Basel). The day of vaginal plug was counted as embryonic 
day 0.5 (e0.5).
Tamoxifen, BrdU and PFT-α administration. Trp53tm1Brn/Hes5::CreERT2/Rosa-CAG::GFP mice were 
given 2 mg Tamoxifen by gavage at e11.5 to induce recombination. Stock solutions of Tamoxifen (Sigma) were 
prepared at a concentration of 20 mg/ml in corn oil (Sigma). Bromodesoxyuridine (BrdU, Sigma) was adminis-
tered to the adult animals via a single intraperitoneal injection (50 mg/kg body weight). PFT-α (stock solution 
20 mM in DMSO) was injected intraperitoneal into pregnant mice (2.2 mg/kg).
In utero electroporation for overexpression in neural stem/progenitors in vivo. Female 
C57BL/6 J and Trp53tm1Brn mice were used for the in utero expression analyses at 13.5 days after detection of 
vaginal plug. DNA constructs were injected into the forebrain telencephalic vesicles of the embryonic mice using 
a microinjector (Pneumatic Pico Pump, WPI Rnage) and pulled Borosilicate glass capillaries (Kwick-FilTM). 
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The capillaries were pulled in a micropipette puller (Sutter Instrument Co.) and sharpened using a capillary sharp-
ener (Bachofer). The capillaries were backend-loaded with 10 μl of the plasmid. Plasmid stocks were prepared 
under endotoxin free conditions and suspended in sterile phosphate buffered saline (PBS) at a concentration 
of 3 μg/μl. Fast green contrast dye (10%) was added to the plasmids to visualize the targeted area of the telen-
cephalon. The overexpression or shRNA knockdown vectors were electroporated in a molecular ratio of 3:1 
with the transfection reporter vector (pCAGGS::eGFP). The pregnant female mice were administered analgesic 
(Temgesic; 0.8 mg/kg) by intraperitoneal injection and anesthetized with 1–2% isoflurane (Baxter) in a con-
stant flow of O2, secured on a heated operating table. Body temperature was monitored continually. The fur 
was removed from the abdomen using depilation cream. Throughout the operation, the peritoneal cavity was 
moistened with sterile Hank’s buffered saline solution (HBSS). The uterine horns containing the embryos (e13.5) 
were manipulated under sterile conditions by hand. A cold light source was used to illuminate the embryos. 
1–2 μl of DNA solution were injected into the telencephalic vesicles of each embryo. The embryos were electro-
porated (Electro Square Pavator™, BTX® Harvard Apparatus) with 10 pulses of 40 V and a pulse length of 50 ms 
at 950 ms intervals. The anode of the electrode was oriented toward the injected side. After injection and elec-
troporation, the uterus was returned to the abdomen, the muscle and the skin sutured and the females allowed 
to recover under a heating lamp with constant observation. Operated females had free postoperative access to 
analgesic (Temgesic; 0.8 mg/kg) in sterile agar. The animals were sacrificed after a defined time and the embryos 
isolated and prepared for sectioning.
Expression plasmids and constructs. Full-length coding region cDNAs for GFP, Cdkn1a, human TDP-43, 
human TDP-43A315T and human TDP-43∆RRM1 were subcloned into pCAGGS expression vectors with a beta-globin 
3-prime untranslated and polyadenylation sequence. pSuper-shRenilla as well as pSuper-shTDP-43 were cloned 
according to the manufacturer’s instructions (Oligoengine). p3X-FLAG-myc-CMVTM-26 expression construct was 
obtained from Sigma and p3X-TDP-43-flag was cloned using Not1 and Xba1 restriction sites (Primers: fwd 5′- 
TTCTGCGGCCGCCACCATGTCTGAATATATTCG-3′ rev 5′-CTTTCTAGACTACATTCCCCAGCCAGAAG-3′).
In situ RNA hybridization. For in situ RNA hybridization a digoxigenin- (DIG)-labeled antisense 
RNA probe was generated for mouse Tardbp RNA (amplified from mouse cDNA using primers: fwd 
5′-ATTCCTTCCCGTCTGTGCTT-3′ rev 5′-TGCTTAGGTTCAGCATTGGA-3′) using the procedures 
described previously. Expression was detected by colorimetric reaction using NBT (nitroblue tetrazolium chlo-
ride) and BCIP (5-bromo-4-chloro-3-indolylphosphate p-toluidine) as reaction substrates and images taken 
using an Axioplan microscope (Zeiss) with an Axiocam CCD camera (Zeiss).
Quantitative real-time PCR analysis of gene expression. For RNA isolation, cells were lysed directly 
in Trizol (Invitrogen) reagent. RNA was prepared according to the manufacturer’s instructions. 1 μg of total 
RNA was used for cDNA synthesis by Oligo-dT priming and BioScript (Bioline). For quantitative RT-PCR the 
SensiMix SYBR kit (Bioline) was used following the manufacturer’s instructions (see Supplemental Materials 
and Methods for detailed description of primers) The reaction was run in a Rotor-GeneTM 6000 Real-time PCR 
machine (Corbett) and analyzed using Rotor-gene 6000 series software 1.7. β-actin and GAPDH mRNA levels 
were measured as endogenous controls and for quantification.
Cross-linked RNA immunoprecipitation. The detailed protocol can be found at http://www.
bio-protocol.org/e398. In summary, N2A cells were transfected using Lipofectamin2000 (Invitrogen) accord-
ing to manufacturer’s instructions with p3X-flag-GFP or p3X-flag-TDP-43 and trypsinized after 48 hours. The 
cells were then fixed in 3% formaldehyde in PBS for 10 minutes and lysed by sonication (10 pulses for 10 sec-
onds). Immunoprecipitation was performed overnight at 4 °C using anti-Flag M2 Affinity Gel (Sigma-Aldrich). 
After collection by centrifugation at 2000g and washing 3–4 times with lysis buffer the complexes were reverse 
cross-linked and RNA extracted using Trizol reagent (Invitrogen) according to the manufacturers instructions. 
Isolated RNA was treated with RNase-free DNaseI (Roche) to remove any genomic DNA contamination. First 
strand cDNA was generated using BioScript (Bioline) and random hexamer primers followed by real-time PCR 
using SensiMix SYBR Kit (Bioline).
Immunoprecipitation and Western blotting. For immunoprecipitation, N2A cells were transfected 
with expression plasmids (p3X-flag-TDP-43 or p3X-flag-GFP as control) and cells were harvested after 24 hours. 
Cells were lysed and 1/10 of the lysate was used as input control. The remaining lysate was added to pre-blocked 
beads coupled to anti-flag antibody (ANTI-FLAG® M2 Affinity Gel) or to un-coupled beads (Sepharose-G beads) 
and incubated at 4 °C. Thereafter the beads with the bound proteins were washed and the samples were incubated 
for 1 hour at 70 °C to release the bound proteins. The supernatant containing the immunoprecipitated proteins 
was then analyzed on a SDS-gel. For low molecular weight proteins like TDP-43, 15% separation gels were used 
according to the manufacturer’s instruction. 20–40 μg proteins with sample loading buffer were denatured and 
loaded on the gel. Proteins were separated and after blotted onto a PVDF membrane. To detect proteins the mem-
brane was incubated with specific antibodies after blocking with blocking buffer for 1 hour (see Supplemental 
Tables for detailed description of antibodies). The membrane was thereafter incubated with a secondary antibody 
coupled to horse reddish peroxidase and the antibody was detected using Amersham™ ECL™ Western Blotting 
Detection reagent.
Immunohistochemistry and immunostaining. Embryos were harvested and the brains fixed in 4% 
paraformaldehyde (PFA) solution in 0.1 M phosphate buffer (PB) overnight. Brains were cryoprotected in a 30% 
sucrose solution in 0.1 M PB for 24 hours, embedded and frozen over dry ice in OCT (TissueTEK). Horizontal 
sections (20 μm) were collected on Superfrost glass slides (Thermo Scientific), and stored at −20 °C until use. 
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For immunostaining, sections were incubated overnight at 4 °C with the primary antibody diluted in blocking 
solution of 2% normal donkey serum (Jackson ImmunoResearch), 0.3% Triton X-100 in 0.1 M PB. Sections were 
washed three times in PBS and incubated at room temperature for 3 hours with the corresponding secondary 
antibodies in blocking solution. When signal amplification was needed, sections were washed and incubated for 
1 hour at room temperature in streptavidin–FITC (Jackson ImmunoResearch; 1:500) and counter-stained with 
DAPI (1 μg/ml). For BrdU detection, sections were treated with 2 M HCl at 37 °C for 15 minutes prior to primary 
antibody incubation. HCl-treated sections where then equilibrated in borate buffer (0.1 M, pH 8.5) for 10 min-
utes. For active caspase-3, Tbr1, Tbr2 and TDP-43 detection, antigens were recovered at 80 °C for 30 minutes 
in Sodium Citrate solution (10 mM, pH 6.0) with 0.05% Tween. Stained sections were embedded in mounting 
medium containing diazabicyclo-octane (DABCO; Sigma) as an anti-fading agent. Antibodies, dilutions and 
conditions used for immunolabeling are described in the supplementary tables. Sections were analyzed with an 
Axioscope (Zeiss) or confocal (Zeiss LSM510) fluorescence microscope. Images were acquired using Axiovision 
or Zeiss LSM 4.2 (Zeiss) and processed with ImageJ 1.33 or Photoshop CS (Adobe) software.
iPS cell culture and fluorescent assisted cell sorting. Human iPS cells (Nas2 cells)48 were differenti-
ated into cerebral cortex neurons for 39 days according to the protocol from Shi et al.37. Patient-derived TDP-
43G298S mutant iPS have been characterized and described previously by Alami et al.38. iPS cells were washed, 
filtered through a 70 µm cell strainer (Miltenyi Biotec) and sorted on a BD FACS Aria III. Live cells were discrimi-
nated by forward and side-scatter (for live cells – from the control) and gated for GFP- (non transfected) or single 
GFP+ populations.
Quantification and statistical analysis of the data. Randomly selected, stained cells were analyzed 
with fixed photomultiplier settings on a Zeiss LSM510 confocal microscope (Zeiss). n numbers represent the 
number of animals used, and images from at least 3 sections per animal were quantified. Data are presented 
as average percentages of co-labeled cells and statistical comparisons were conducted by two-tailed unpaired 
Student’s tTest. Significance was established at P < 0.05. In all graphs, error bars are standard deviation (SD).
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